Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Investigation of Efficacy and Safety of EPOGAM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00878670
Recruitment Status : Completed
First Posted : April 9, 2009
Last Update Posted : January 26, 2012
Information provided by (Responsible Party):
Max Zeller Soehne AG

Brief Summary:
In this study it will be investigated if patients with atopic dermatitis responding to EPOGAM treatment, show a significant increase of dihomo-gamma-linolic acid in the blood.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Neurodermatitis Drug: EPOGAM 1000 Phase 4

Detailed Description:
Patients with atopic dermatitis will receive EPOGAM 1000 for 12 weeks. Clinical symptoms of the disease will be assessed using the SCORAD score. Dihomo-gamma-linolic acid levels in the blood will be measured with GC-MS.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study)
Study Start Date : March 2009
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Intervention Details:
  • Drug: EPOGAM 1000
    One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
    Other Names:
    • Oenothera seminis oleum
    • Evening Primrose Oil
    • EPOGAM

Primary Outcome Measures :
  1. Levels of dihomo-gamma linolic acid in the blood [ Time Frame: 0, 4 and 12 weeks after start of treatment ]
  2. Efficacy of EPOGAM 1000 treatment on the symptoms of atopic dermatitis [ Time Frame: 0, 4 and 12 weeks after start of treatment ]

Secondary Outcome Measures :
  1. Assessment of the efficacy of EPOGAM 1000 treatment by the patient on a visual analog scale [ Time Frame: 4 and 12 weeks after start of treatment ]
  2. Assessment of the symptoms itching, sleep disorder, skin sensation, skin condition by the patient on a visual analog scale [ Time Frame: 4 and 12 weeks after start of treatment ]
  3. Willingness of the patient to further take the medication and assessment of problems related to the intake of the study drug. [ Time Frame: 12 weeks after start of treatment ]
  4. Assessment of the efficacy of EPOGAM treatment by the investigator [ Time Frame: 4 and 12 weeks after start of treatment ]
  5. Assessment of adverse events (AE) [ Time Frame: During treatment (12 weeks) ]
  6. Physical examination [ Time Frame: 0, 4 and 12 weeks after start of treatment ]
  7. Laboratory values (blood examination) [ Time Frame: 0, 4 and 12 weeks after start of the treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • atopic dermatitis since at least 2 months (criteria after Hanifin and Rajka, 1980)
  • men or women aged 2 - 45 years
  • women of childbearing age using contraception
  • informed consent of the patient or of the parents

Exclusion Criteria:

  • psychiatric disorder
  • abuse of drugs or alcohol
  • chronic dermatosis
  • glaucoma, cataract or ocular herpes simplex
  • Immune deficiency
  • Immunological diseases
  • clinical relevant changes in laboratory parameters
  • congenital diseases
  • scabies, infections with dermathophytae, HIV-associated dermatosis
  • malignant diseases
  • metabolic diseases
  • parasites
  • patients enrolled in other studies
  • progredient, systemic diseases
  • pregnancy and lactation
  • severe internistic diseases
  • organ transplantation in the medical history
  • hypersensitivity against an ingredient of the study medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00878670

Layout table for location information
Children Clinic, Canton Hospital Aarau
Aarau, Argau, Switzerland, 5001
University Hospital Zurich
Zurich, Switzerland, CH-8091
Sponsors and Collaborators
Max Zeller Soehne AG
Layout table for investigator information
Principal Investigator: Peter Grendelmeier, MD University Clinic Zurich

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Max Zeller Soehne AG Identifier: NCT00878670    
Other Study ID Numbers: Ze 358 2008.01
First Posted: April 9, 2009    Key Record Dates
Last Update Posted: January 26, 2012
Last Verified: January 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Evening primrose oil
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Dermatologic Agents